Clinical Data AAIC 2026: Lilly keeps door open for maintenance Kisunla after amyloid clearance BioSpaceEli Lilly's anti-amyloid Alzheimer's drug is designed to be stopped after patients drop below a certain amyloid level in the brain.NeuroscienceRead full story pharminent July 15, 2026 (Last updated: July 17, 2026) BioSpace Eli Lilly’s anti-amyloid Alzheimer’s drug is designed to be stopped after patients drop below a certain amyloid level in the brain. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Celcuity gets FDA nod for first-in-class breast cancer drugNext: J&J Streamlines Pharma Supply Chain Amid $55B US Manufacturing Push Related Stories Clinical Data Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs pharminent July 14, 2026 Clinical Data Major trial launched to explore GLP-1 benefit in dementia pharminent July 13, 2026 Clinical Data GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China pharminent July 10, 2026
